You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CME / ABIM MOC

The New Climate of Bruton Tyrosine Kinase Inhibitors: Winter Meeting Effects on the Management of CLL and MCL

  • Authors: Jennifer A. Woyach, MD; Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath
  • CME / ABIM MOC Released: 12/30/2022
  • Valid for credit through: 12/30/2023, 11:59 PM EST
Start Activity

  • Credits Available

    Physicians - maximum of 0.50 AMA PRA Category 1 Credit(s)™

    ABIM Diplomates - maximum of 0.50 ABIM MOC points

    You Are Eligible For

    • Letter of Completion
    • ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists and pathologists.

The goal of this activity is to enable learners to understand the latest clinical trial data with BTK inhibitors for B-cell malignancies (eg, chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL] and mantle cell lymphoma [MCL]) and the possible implications for current and future clinical practice to continue advancing patient outcomes.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Latest clinical trial data with BTK inhibitors for CLL/SLL
    • Latest clinical trial data with BTK inhibitors for MCL
  • Demonstrate greater confidence in their ability to
    • Integrate the latest data with BTK inhibitors into the treatment algorithm for patients with B-cell malignancies


Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.


Faculty

  • Jennifer A. Woyach, MD

    Professor of Medicine
    Division of Hematology
    The Ohio State University
    Comprehensive Cancer Center
    Columbus, Ohio, United States

    Disclosures

    Jennifer A. Woyach, MD, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd.; Genentech; Loxo Oncology; Newave; Pharmacyclics
    Research funding from: Janssen; Karyopharm; MorphoSys; Pharmacyclics, Inc.
    Contracted researcher for: Schrodinger

  • Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath

    Consultant
    Hematology
    Oxford Cancer and Haematology Centre
    Churchill Hospital
    Oxford University Hospitals NHS Foundation Trust
    Oxford, United Kingdom

    Disclosures

    Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath, has the following relevant financial relationships:
    Consultant or advisor for: AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd.; Gilead; Incyte Corporation; Janssen; Kite Pharma, Inc.; Loxo Oncology; Roche; Secura Bio
    Speaker or member of speakers bureau for: AbbVie, Inc.; AstraZeneca Pharmaceuticals LP; Gilead; Incyte Corporation; Janssen; Kite Pharma, Inc.; Loxo Oncology; Roche; Takeda
    Research funding from: AstraZeneca Pharmaceuticals LP; BeiGene (Beijing) Co., Ltd.
    Contracted researcher for: Loxo Oncology

Editors

  • Sanneke Koekkoek

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Sanneke Koekkoek, has no relevant financial relationships.

  • Chii Shyang Fong, PhD

    Scientific Content Manager, WebMD Global, LLC

    Disclosures

    Chii Shyang Fong, PhD, has no relevant financial relationships.

Compliance Reviewer

  • Amanda Jett, PharmD, BCACP

    Associate Director, Accreditation and Compliance, Medscape, LLC

    Disclosures

    Amanda Jett, PharmD, BCACP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.


Accreditation Statements

Medscape

Interprofessional Continuing Education

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    For Physicians

  • Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

    Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.

Follow these steps to earn CME/CE credit*:

  1. Read the target audience, learning objectives, and author disclosures.
  2. Study the educational content online or printed out.
  3. Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

CME / ABIM MOC

The New Climate of Bruton Tyrosine Kinase Inhibitors: Winter Meeting Effects on the Management of CLL and MCL

Authors: Jennifer A. Woyach, MD; Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPathFaculty and Disclosures

CME / ABIM MOC Released: 12/30/2022

Valid for credit through: 12/30/2023, 11:59 PM EST

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Review of Latest Data on BTK Inhibitors in Relapsed/Refractory CLL/SLL

In this video, Dr Woyach summarizes data from key selected abstracts of BTK inhibitors in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) presented at the winter conference 2022.
Jennifer A. Woyach, MD

Discussion of Clinical Implications of New Data in Relapsed/Refractory CLL/SLL

Dr Eyre and Dr Woyach share their insights on the role of covalent and noncovalent BTK inhibitors in R/R CLL/SLL.
Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath; Jennifer A. Woyach, MD

Review of Latest Data on BTK Inhibitors in Relapsed/Refractory MCL

Join Dr Eyre for a summary of key selected abstracts of BTK inhibitors in R/R mantle cell lymphoma (MCL) presented at the winter conference 2022.
Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath

Discussion of Clinical Implications of New Data in Relapsed/Refractory MCL

Dr Woyach and Dr Eyre discuss the latest data on BTK inhibitors in R/R MCL and their impact on clinical practice.
Jennifer A. Woyach, MD; Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath
 

Learning Feedback Questions

Please answer these questions to complement your learning experience.

  • Print